Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors | Zendy

Kari R. Irvine | Zendy; Ronald S. Chamberlain | Zendy; Eliza Shulman | Zendy; Deborah R. Surman | Zendy; Steven A. Rosenberg | Zendy; Nicholas P. Restifo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors

Author(s) -

Kari R. Irvine,

Ronald S. Chamberlain,

Eliza Shulman,

Deborah R. Surman,

Steven A. Rosenberg,

Nicholas P. Restifo

Publication year - 1997

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/89.21.1595

Subject(s) - virology , heterologous , biology , antigen , recombinant dna , cytotoxic t cell , vaccination , immune system , modified vaccinia ankara , immunology , vaccinia , gene , genetics , in vitro

The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research